CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 243 enrolled
Drug / intervention
Selegiline +1 moredrug
Likely dose
Selegiline 6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01330030
NCT01330030Phase 2Completed
CompareCT.gov

Selegiline Patch for Treatment of Nicotine Dependence

Stanford University·interventional·Posted Apr 6, 2011·Updated Aug 10, 2016

In Brief

A Phase 2 clinical trial evaluating Selegiline and matching placebo for Tobacco Use Disorder. Completed, enrolled 243 participants across 1 site.

Detailed Summary

Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 6, 2011
Enrollment StartJul 1, 2005
Primary CompletionAug 1, 2008
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.2 years ago

Interventions

Selegilinedrug

6mg/24 hrs for 8 weeks

matching placeboother

placebo/24hrs for 8 weeks